Table 3.
Bivariate analysis of risk factors associated with a virological outcome of HIV-1 RNA <200 copies/mL at week 48 of antiretroviral treatment
| Risk factor | Bivariate | P value | |
|---|---|---|---|
| OR unadjusted | 95% CI | ||
| Male sex | 0.413 | 0.113–1.506 | 0.234 |
| Age >40 years | 4.66 | 1.47–14.72 | 0.005 |
| Number of previous regimens >6 | 0.64 | 0.18–2.24 | 0.490 |
| Baseline HIV‐1 RNA >100,000 copies/mL | 0.43 | 0.13–1.43 | 0.171 |
| Baseline CD4+ cell count <200 cells/μL | 0.40 | 0.13–1.18 | 0.091 |
| GSS ≥2 | 1.67 | 0.55-5.10 | 0.361 |
| TDF | 0.19 | 0.04–0.88 | 0.025 |
| ETV | 2.80 | 0.59–13.19 | 0.229 |
| EFV | 1.09 | 1.02–1.16 | 0.603 |
| MVC | 1.09 | 1.02–1.16 | 0.603 |
| ENF | 0.535 | 0.13–2.20 | 0.408 |
CI confidence interval, EFV efavirenz, ENF enfuvirtide, ETV etravirine, GSS genotypic sensitivity score, MVC maraviroc, OR odds ratio, TDF tenofovir